comprehensive -WSS

comprehensive

author：fashion 2025-09-29 22:38:21 - browse：9

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Paying for Covid pills will soon shift to insurers

focus

leisure time

WSS

Mitch McConnell episode has important public health takeaway

Vertex non

Amazon expands telehealth clinic nationwide

Diversifying clinical trials isn't enough to close racial gaps: study

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

hotspot

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Novavax promises a turnaround & Lilly roils the obesity market

Eli Lilly to pay $200M for Beam’s stake in gene

Psychedelics group wrestles with new pharma identity

Wildfire pollution widens asthma inequities on Long Island

At least 13 dead in Texas as scorching temps continue

WHO may add ‘noma' to its list of neglected tropical diseases

Duchenne breakthrough therapy leaves behind pioneering families

Senate panel to vote on hospitals, PBMs, prisoner care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: New research from Sanofi, Regeneron, etc.

entertainment

Cassava reveals details — and problems — with Alzheimer's study

Emergency medicine has repudiated 'excited delirium.' Now what?

The FDA weighs the risks of candy

Adults seen as increasingly susceptible to measles

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

Readout Newsletter: New research from Sanofi, Regeneron, etc.

focus

leisure time

knowledge

hotspot